Med news

The Med News was a newsletter published from 1960-1962 by the Student American Medical Association (SAMA) at Boston University School of Medicine

Baryogenesis, Domain Walls and the Role of Gravity

It has been recently speculated that global symmetries are broken by gravity. We propose a scenario for the generation of the baryon asymmetry in the early Universe in which the domain walls predicted by theories with discrete symmetries become unstable due to these Planck scale effects. The relative motion of the decaying walls can provide a mechanism for the departure from thermal equilibrium necessary to have a nonvanishing baryon asymmetry. In particular, we implement this idea within the frameworks of the Left-Right and Quark-Lepton symmetric models.Comment: 15 pages (LaTeX), PURD-TH-93-06, SISSA-/93/49-

Ultrasound-Guided Glenohumeral Joint Injection Using the Posterior Approach

Injection treatment to the glenohumeral joint is often needed to treat shoulder problems such as adhesive capsulitis. This can be done through blind palpation technique and fluoroscopic or musculoskeletal ultrasound guidance. In recent years, ultrasound has been proven to increase the accuracy of needle placement into the glenohumeral joint. Ultrasound is radiation free and offers real-time images in performing needle-guided injection procedures. Glenohumeral joint injection can be done using the anterior rotator interval approach or the posterior approach technique. Both techniques are generally well tolerated by the patients. However, it was shown that the posterior injection technique offers an easier and a more effective approach to the glenohumeral joint with less extravasation rate as compared with the anterior approach. The posterior approach also avoids the potential risk of accidental puncture or injection into the axillary neurovascular structures. A linear transducer of 5–12 MHz is usually used. This technique is often applied to inject corticosteroid for the treatment of frozen shoulder or contrast medium for computed tomography or magnetic resonance shoulder arthrography

Baryogenesis through Collapsing String Loops in Gauged Baryon and Lepton Models

A scenario for the generation of the baryon asymmetry in the early Universe is proposed in which cosmic string loops, predicted by theories where the baryon and/or lepton numbers are gauged symmetries, collapse during the friction dominated period of string evolution. This provides a mechanism for the departure from thermal equilibrium necessary to have a nonvanishing baryon asymmetry. Examples of models are given where this idea can be implemented. In particular, the model with the gauge symmetry $SU(3)_{c}\otimes SU(2)_{L}\otimes U(1)_{Y}\otimes U(1)_{B} \otimes U(1)_{L}$ has the interesting feature where sphaleron processes do not violate the baryon and lepton numbers so that no wash out of any initial baryon asymmetry occurs at the electroweak scale.Comment: 21 pages, LaTeX, PURD-TH-93-09, SISSA 87/93/

In What Ways Are Deep Neural Networks Invariant and How Should We Measure This?

It is often said that a deep learning model is "invariant" to some specific type of transformation. However, what is meant by this statement strongly depends on the context in which it is made. In this paper we explore the nature of invariance and equivariance of deep learning models with the goal of better understanding the ways in which they actually capture these concepts on a formal level. We introduce a family of invariance and equivariance metrics that allows us to quantify these properties in a way that disentangles them from other metrics such as loss or accuracy. We use our metrics to better understand the two most popular methods used to build invariance into networks: data augmentation and equivariant layers. We draw a range of conclusions about invariance and equivariance in deep learning models, ranging from whether initializing a model with pretrained weights has an effect on a trained model's invariance, to the extent to which invariance learned via training can generalize to out-of-distribution data.Comment: To appear at NeurIPS 202

Nanostructures Technology, Research, and Applications

Contains reports on twenty research projects and a list of publications.Joint Services Electronics Program Contract DAAL03-92-C-0001Semiconductor Research Corporation Contract 94-MJ-550U.S. Army Research Office Grant DAAL03-92-G-0291Advanced Research Projects Agency/Naval Air Systems Command Contract N00019-92-K-0021National Science Foundation Grant ECS 90-16437National Science Foundation Grant ECS 90-16737IBM Corporation Contract 1622U.S. Air Force - Office of Scientific Research Grant F-49-62-92-J-0064National Science Foundation Grant DMR 87-19217National Science Foundation Grant DMR 90-22933National Aeronautics and Space Administration Contract NAS8-3674

Submicron and Nanometer Structures Technology and Research

Contains reports on twenty research projects and a list of publications.Defense Advanced Research Projects Agency Contract N00019-92-K-0021Joint Services Electronics Program Contract DAAL03-92-C-0001National Science Foundation Grant ECS 90-16437U.S. Army Research Office Grant DAAL03-92-G-0291IBM CorporationU.S. Air Force - Office of Scientific Research Grant F49620-92-J-0064National Science Foundation Grant DMR 87-19217National Science Foundation Grant DMR 90-22933Defense Advanced Research Projects Agency Consortium for Superconducting ElectronicsNational Aeronautics and Space Administration Contract NAS8-36748National Aeronautics and Space Administration Grant NAGW-200

Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe

Objective To evaluate the frequency with which relevant and accurate information about the benefits and related uncertainties of anticancer drugs are communicated to patients and clinicians in regulated information sources in Europe. Design Document content analysis. Setting European Medicines Agency. Participants Anticancer drugs granted a first marketing authorisation by the European Medicines Agency, 2017-19. Main outcome measures Whether written information on a product addressed patients’ commonly asked questions about: who and what the drug is used for; how the drug was studied; types of drug benefit expected; and the extent of weak, uncertain, or missing evidence for drug benefits. Information on drug benefits in written sources for clinicians (summaries of product characteristics), patients (patient information leaflets), and the public (public summaries) was compared with information reported in regulatory assessment documents (European public assessment reports). Results 29 anticancer drugs that received a first marketing authorisation for 32 separate cancer indications in 2017-19 were included. General information about the drug (including information on approved indications and how the drug works) was frequently reported across regulated information sources aimed at both clinicians and patients. Nearly all summaries of product characteristics communicated full information to clinicians about the number and design of the main studies, the control arm (if any), study sample size, and primary measures of drug benefit. None of the patient information leaflets communicated information to patients about how drugs were studied. 31 (97%) summaries of product characteristics and 25 (78%) public summaries contained information about drug benefits that was accurate and consistent with information in regulatory assessment documents. The presence or absence of evidence that a drug extended survival was reported in 23 (72%) summaries of product characteristics and four (13%) public summaries. None of the patient information leaflets communicated information about the drug benefits that patients might expect based on study findings. Scientific concerns about the reliability of evidence on drug benefits, which were raised by European regulatory assessors for almost all drugs in the study sample, were rarely communicated to clinicians, patients, or the public. Conclusions The findings of this study highlight the need to improve the communication of the benefits and related uncertainties of anticancer drugs in regulated information sources in Europe to support evidence informed decision making by patients and their clinicians

Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages

Generalist and specialist species differ in the breadth of their ecological niches. Little is known about the niche width of obligate human pathogens. Here we analyzed a global collection of Mycobacterium tuberculosis lineage 4 clinical isolates, the most geographically widespread cause of human tuberculosis. We show that lineage 4 comprises globally distributed and geographically restricted sublineages, suggesting a distinction between generalists and specialists. Population genomic analyses showed that, whereas the majority of human T cell epitopes were conserved in all sublineages, the proportion of variable epitopes was higher in generalists. Our data further support a European origin for the most common generalist sublineage. Hence, the global success of lineage 4 reflects distinct strategies adopted by different sublineages and the influence of human migration.We thank S. Lecher, S. Li and J. Zallet for technical support. Calculations were performed at the sciCORE scientific computing core facility at the University of Basel. This work was supported by the Swiss National Science Foundation (grants 310030_166687 (S.G.) and 320030_153442 (M.E.) and Swiss HIV Cohort Study grant 740 to L.F.), the European Research Council (309540-EVODRTB to S.G.), TB-PAN-NET (FP7-223681 to S.N.), PathoNgenTrace projects (FP7-278864-2 to S.N.), SystemsX.ch (S.G.), the German Center for Infection Research (DZIF; S.N.), the Novartis Foundation (S.G.), the Natural Science Foundation of China (91631301 to Q.G.), and the National Institute of Allergy and Infectious Diseases (5U01-AI069924-05) of the US National Institutes of Health (M.E.)